Cargando…
ICAM‐1‐targeted nanocarriers attenuate endothelial release of soluble ICAM‐1, an inflammatory regulator
Targeting of drug nanocarriers (NCs) to intercellular adhesion molecule‐1 (ICAM‐1), an endothelial‐surface protein overexpressed in many pathologies, has shown promise for therapeutic delivery into and across this lining. However, due to the role of ICAM‐1 in inflammation, the effects of targeting t...
Autores principales: | Manthe, Rachel L., Muro, Silvia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510616/ https://www.ncbi.nlm.nih.gov/pubmed/28713860 http://dx.doi.org/10.1002/btm2.10050 |
Ejemplares similares
-
Biodistribution and endocytosis of ICAM-1-targeting antibodies versus nanocarriers in the gastrointestinal tract in mice
por: Mane, Viraj, et al.
Publicado: (2012) -
IFN-gamma regulation of ICAM-1 receptors in bronchial epithelial cells: soluble ICAM–1 release inhibits human rhinovirus infection
por: Whiteman, Suzanne C, et al.
Publicado: (2008) -
Tuning Design Parameters of ICAM-1-Targeted 3DNA Nanocarriers to Optimize Pulmonary Targeting Depending on Drug Type
por: Roki, Nikša, et al.
Publicado: (2022) -
Morphine Postconditioning Attenuates ICAM-1 Expression on Endothelial Cells
por: Min, Too Jae, et al.
Publicado: (2011) -
Measuring Soluble ICAM-1 in African Populations
por: Abdi, Abdirahman I., et al.
Publicado: (2014)